Jennifer Cook, currently the Head of Clinical Operations in Product Development for Roche, will take over the reins of GRAIL in the new year.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
An immuno-oncology drug that’s in the works could generate significant revenue growth someday.
Sanofi’s Admelog is the first meal-time insulin copy the FDA has approved.
Gilead Sciences has acquired start-up Cell Design Labs, after a growing interest in ways to battle disease using engineered immune cells.
Chinese chemical manufacturing firm Boai NKY Pharmaceuticals plans to purchase BioVision Inc., a drug screening specialist headquartered in San Francisco.
Two major pharma companies express concerns that attracting and retaining the right talent could still be a problem, following UK Government’s £1bn deal.
Spark Therapeutics’ gene therapy for patients with haemophilia has seen some early success in clinical trials, after being tested in 10 male patients
We caught up to Macrogen at ASHG, to speak about their latest CAP accreditation, and what benefits this will bring them in the next year.
The UK government has signed a deal with 25 global organisations that aims to boost life sciences research and investment in the UK.
Drugs reviewed by the FDA in programs intended to speed drug development were approved nearly a year quicker than drugs reviewed through normal processes.
Celgene, a company with a market cap of $80 billion and expectations to grow sales by 14.5% annually through 2020 might be the answer to Pfizer’s woes.
As the year draws to a close, Rick Duprey, writing for The Motley Fool, takes a look back at three biotechs that have quadrupled this year.
Congress is working on a tax overhaul. But it turns out the tax bills in the House and Senate also aim to reshape health care.
This year’s Breakthrough Prizes went to researchers working in cell biology, neurobiology, plant biology, astrophysics, and mathematics.